Arzu ORAL YILMAZTEPE, Mehmet SARIMAHMUT, Engin ULUKAYA, Haluk Barbaros ORAL, Güven ÖZKAYA, Şeniz KORKMAZ, Buse CEVATEMRE

Combination of esomeprazole with chemotherapeutics results in more pronounced cytotoxic effect via apoptosis on A549 nonsmall-cell lung cancer cell line

The vacuolar (H+)-ATPases that pump H+ from the cytoplasm to extracellular compartments can alter the pH of the tumor microenvironment. Esomeprazole can effectively inhibit vacuolar (H+)-ATPases and may increase the effectiveness of chemotherapeutics. Therefore, we used esomeprazole in combination with cisplatin, carboplatin, paclitaxel, docetaxel, gemcitabine, and vinorelbine on the A549 nonsmall-cell lung cancer cell line. Cisplatin and carboplatin combinations with esomeprazole exhibited superior cytotoxicity compared to the other selected chemotherapeutics. Low-dose combinations of esomeprazole with either cisplatin or carboplatin resulted in synergistic interaction. We examined cytotoxic activity of these combinations with the xCELLigence real-time cytotoxicity assay and detected that esomeprazole combinations with both 100% test drug concentrations of cisplatin and carboplatin shifted the antiproliferative effects of these agents towards a cytotoxic effect in a dose-dependent manner. Cell death mode was investigated by M30 assay, Annexin-V-FITC fluorescence imaging, and determination of PARP cleavage in western blotting. The cells treated with the cisplatin and esomeprazole combination displayed characteristic features of apoptosis such as elevated M30 levels, Annexin-V staining, and PARP cleavage. In conclusion, these novel combinations resulted in higher sensitivity of tumors to chemotherapeutics, thereby warranting further in vivo experiments for proof of the concept.

PDF

___

Altan N, Chen Y, Schindler M, Simon SM (1998). Defective acidification in human breast tumor cells and implications for chemotherapy. J Exp Med 187: 1583-1598.
Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Untch M et al. (1995). Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55: 5276-5282.
Booker V, Halsall C, Llewellyn N, Johnson A, Williams R (2014). Prioritising anticancer drugs for environmental monitoring and risk assessment purposes. Sci Total Environ 473: 159-170.
Brana I, Ocana A, Chen EX, Razak AR, Haines C, Lee C, Douglas S, Wang L, Siu LL, Tannock IF et al. (2014). A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. Invest New Drugs 32: 1269-1277.
Caldarella A, Crocetti E, Comin CE, Janni A, Pegna AL, Paci E (2007). Gender differences in non-small cell lung cancer: a population-based study. Eur J Surg Oncol 33: 763-768.
Carter-Harris L, Hermann CP, Schreiber J, Weaver MT, Rawl SM (2014). Lung cancer stigma predicts timing of medical helpseeking behavior. Oncol Nurs Forum 41: E203.
Chou TC (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681.
Chou TC (2010). Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70: 440-446.
Chung C, Mader CC, Schmitz JC, Atladottir J, Fitchev P, Cornwell ML, Koleske AJ, Crawford SE, Gorelick F (2011). The vacuolarATPase modulates matrix metalloproteinase isoforms in human pancreatic cancer. Lab Invest 91: 732-743.
De Milito A, Canese R, Marino ML, Borghi M, Iero M, Villa A, Venturi G, Lozupone F, Iessi E, Logozzi M et al. (2010). pHdependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer 127: 207-219.
De Milito A, Iessi E, Logozzi M, Lozupone F, Spada M, Marino ML, Federici C, Perdicchio M, Matarrese P, Lugini L et al. (2007). Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res 67: 5408-5417.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 (Internet). Lyon, France: International Agency for Research on Cancer; 2013.
Garcia-Garcia, A, Perez-Sayans Garcia M, Rodriguez MJ, AntúnezLópez J, Barros-Angueira F, Somoza-Martín M, GándaraRey JM, Aguirre-Urízar JM (2012). Immunohistochemical localization of C1 subunit of V-ATPase (ATPase C1) in oral squamous cell cancer and normal oral mucosa. Biotech Histochem 87: 133-139.
Gatenby RA, Gillies RJ (2004). Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891-899.
Izumi H, Torigoe T, Ishiguchi H, Uramoto H, Yoshida Y, Tanabe M, Ise T, Murakami T, Yoshida T, Nomoto M et al. (2003). Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat Rev 29: 541-549.
Leers MP, Kolgen W, Björklund V, Bergman T, Tribbick G, Persson B, Björklund P, Ramaekers FCS, Björklund B, Nap M et al. (1999). Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187: 567-572.
Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK (2000). Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res 60: 4324-4327.
Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, Marra M, Lugini L, Logozzi M, Lozupone F et al. (2004). Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 96: 1702- 1713.
Mahoney BP, Raghunand N, Baggett B, Gillies RJ (2003). Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol 66: 1207-1218.
Martinez-Zaguilan R, Raghunand N, Lynch RM, Bellamy W, Martinez GM, Rojas B, Smith D, Dalton WS, Gillies RJ (1999). pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines. Biochem Pharmacol 57: 1037-1046.
Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, Hendrix MJ (1996). Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastas 14: 176-186.
Morita T, Nagaki T, Fukuda I, Okumura K (1992). Clastogenicity of low pH to various cultured mammalian cells. Mutat Res 268: 297-305.
Murakami T, Shibuya I, Ise T, Chen ZS, Akiyama SI, Nakagawa M, Izumi H, Nakamura T, Matsuo K, Yamada Y et al. (2001). Elevated expression of vacuolar proton pump genes and cellular pH in cisplatin resistance. Int J Cancer 93: 869-874.
Nishi T, Forgac M (2002). The vacuolar (H+)-ATPases--natures most versatile proton pumps. Nat Rev 3: 94-103.
Padera TP, Kadambi A, Di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark EJ et al. (2002). Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296: 1883-1886.
Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, Rey JMG, Garcia-Garcia A (2009). V-ATPase inhibitors and implication in cancer treatment. Cancer Treat Rev 35: 707-713.
Qiang L, Lu S, Huang L, Wang T, Wan Y, Zhou CX, Zhang C, Zhang Z, Li X (2013). The expression of V-ATPase is associated with drug resistance and pathology of non-small-cell lung cancer. Diagn Pathol 8: 145-152.
Raghunand N, He X, Van Sluis R, Mahoney B, Baggett B, Taylor CW, Paine-Murrieta G, Roe D, Bhujwalla ZM, Gillies RJ (1999a). Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer 80: 1005-1011.
Raghunand N, Mahoney B, Van Sluis R, Baggett B, Gillies RJ (2001). Acute metabolic alkalosis enhances response of C3H mouse mammary tumors to the weak base mitoxantrone. Neoplasia 3: 227-235.
Raghunand N, Mahoney BP, Gillies RJ (2003). Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. Biochem Pharmacol 66: 1219-1229.
Raghunand N, Martinez-Zaguilan R, Wright SH, Gillies RJ (1999b). pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs. Biochem Pharmacol 57: 1047-1058.
Robinson M (2001). New-generation proton pump inhibitors: overcoming the limitations of early-generation agents. Eur J Gastroenterol Hepatol 13: S43-47.
Schutte B, Henfling M, Kölgen W, Bouman M, Meex S, Leers MP, Nap M, Björklund V, Björklund P, Björklund B et al. (2004). Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res 297:11-26.
Sennoune SR, Bakunts K, Martinez GM, Chua-Tuan JL, Kebir Y, Attaya MN, Martínez-Zaguilán, R (2004). Vacuolar H+- ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol 286: 1443-1452.
Shi S, Klotz U (2008). Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 64: 935-951.
Shim J, Brindle L, Simon M, George S (2014). A systematic review of symptomatic diagnosis of lung cancer. Fam Pract 31: 137-148.
Simon S, Roy D, Schindler M (1994). Intracellular pH and the control of multidrug resistance. P Natl Acad Sci USA 91: 1128-1132.
Tannock IF, Rotin D (1989). Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 49: 4373-4384.
Torigoe T, Izumi H, Ise T, Murakami T, Uramoto H, Ishiguchi H, Yoshida Y, Tanabe M, Nomoto M, Kimitoshi K (2002). Vacuolar H(+)-ATPase: functional mechanisms and potential as a target for cancer chemotherapy. Anticancer Drugs 13: 237-243.
Ueno T, Toi M, Biven K, Bando H, Ogawa T, Linder S (2003). Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer 39: 769-774.
Ulukaya E, Ozdikicioglu F, Oral AY, Demirci M (2008). The MTT assay yields a relatively lower result of growth inhibition than the ATP assay depending on the chemotherapeutic drugs tested. Toxicol In Vitro 22: 232-239.
Van Den Berg AP, Wike-Hooley JL, Van Den Berg-Blok AF, Van Der Zee J, Reinhold HS (1982). Tumour pH in human mammary carcinoma. Eur J Cancer Clin On 18: 457-462.
Vaupel P (2004). Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14: 198-206.
Wagner CA, Finberg KE, Breton S, Marshansky V, Brown D, Geibel JP (2004). Renal vacuolar H+-ATPase. Physiol Rev 84: 1263- 1314.
Wang BY, Zhang J, Wang JL, Sun S, Wang ZH, Wang LP, Zhang QL, Lv FF, Cao EY, Shao ZM et al. (2015). Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. J Exp Clin Canc Res 34: 85.